valu usd unless otherwis note
cautiou margin outlook dividend larg
initi sp price target
view pend acquisit bolster size
humira loe fail address growth issu despit favor swing
sentiment growth issu could chang subsequ strateg
move also think street underestim margin
headwind stock sinc mid-august await better
entri point meantim dividend valuat add support
agn deal fulli address humira loe
pro-forma revenu stand-alone npv
upcom humira biosimilar impact well understood
think initi magnitud step-down still under-appreci bolster
overal revenu base leav compound-annual-growth-rate unchang
scale add attract medic aesthet
mix overal deal see opportun address via
divestitur includ medic aesthet time leav manag
abil break unlock valu
see structur margin step-down beyond
primari reason street model oper
margin move basi
point consensu drive ep delta humira part
impact greater contribut partner
imbruvica venclexta margin pressur margin
step-down flat revenu base leav us
declin pro-forma ep peak
six product remain backbon stori compris
revenu grow compound-annual-growth-rate
street skyrizi rinvoq launch strong start
line imbruvica calquenc competit debat continu
venclexta orilissa disappoint earli launch
botox competit pressur lower growth
busi deem less core compris revenu
compound-annual-growth-rate leav question manag around potenti
divestitur could push consolid growth modestli higher
think opportun exist recogn deal yet close
hard ignor near sector-low valuat sector-
high dividend yield differenti part
investor focus dividend incom acquisit add support
recent announc decis increas dividend
think understood sentiment markedli improv
stock august low sell-sid rate
buy versu april last year deal
price prior trade day market close estimate unless otherwis note
bloomberg capit market estim upside/downside/target
base case scenario see price target impli
price-to-earnings pro-forma ep
assum earli deal close allergan specif
addit accret built estim expect
limit impact hem-onc franchis competit
strong uptak key growth product skyrizi
upsid case scenario see price target impli
price-to-earnings pro-forma ep
faster uptak key growth product skyrizi
assum earli deal close allergan addit
accret built estim
lower humira eros follow us loss exclus
expect
limit impact hem-onc franchis competit
downsid case scenario see price target
impli price-to-earnings pro-forma ep
sluggish uptak key growth product skyrizi
assum prolong deal closur allergan and/or
stringent ftc divestitur requir expect
aggress humira eros follow us loss
exclus expect
meaning impact hem-onc franchis competit
faster convers anticip
invest thesi multi-year outlook
pressur compani work
us humira loss exclus loe replac
gap lower-margin asset announc allergan
acquisit expect close earli legaci
portfolio struggl strateg fit
allergan deal serv help combin compani
navig loe provid suffici cash flow support
continu strateg deploy capit thesi base
follow key point support sector perform
allergan acquisit help compani navig
humira cliff see opportun divest lower
growth asset addit provid attract add
product dilut growth profil combin
compani said see potenti futur strateg
action could creat valu ie divest non-cor
franchis bolster cash flow near-term
high growth product insuffici drive top-line
growth combin compani pressur outer-
year margin expect combin newco drive flat
top-line growth margin pressur
humira loe allergan product mix impact
growth lower-margin hem/onc franchis
limit meaning busi develop abbvi
digest allergan deal focus debt paydown
commit grow dividend also pay
billion debt end
paydown beyond flexibl around
smaller deal expect see execut anyth
meaning near-term could move needl
potenti catalyst close allergan acquisit earli
updat around divestitur hurdl
close sever data read focu rinvoq ph data
atop derm skyrizi ph uc bi
voltaire-x interchang studi read-out biosimilar
humira head-to-head calquence/imbruvica data r/r
risk thesi delay close allergan deal and/or
risk particularli around hem-onc franchis botox
slower uptak key grower regulatory/polit risk
read-through price
grow
humira patent cliff
acquisit allergan
risk growth declin
repres real risk imbruvica
much
properli posit
benefit signific growth
opportun expect come
china meaning
 come year
abbvi cash flow
support follow allergan
acquisit maintain best
class dividend continu
estim reflect flattish revenu growth without allergan
transact legaci model compani reflect flat top-lin
period exclud humira declin
anticip biosimilar entri see growth remain busi
core grower immunolog hematolog oncolog medic
aesthet deliv even faster compound-annual-growth-rate overal think
abbvi fast grow product off-set impact humira leav
combin pro-forma revenu base follow allergan close roughli
billion per year next year
calquenc data appear show mix benefit rel imbruvica
expect meaning drive share away imbruvica
focu r/r head-to-head data imbruvica import product
pro-forma revenu understand expect investor
focu remain high follow approv astrazeneca calquenc
cll look gener head-to-head data compound-annual-growth-rate
grow pro-forma revenu despit lower margin
profil product given profit share janssen import
growth product compani cornerston hem/onc franchis
chronic
lymphocyt leukemia cll imbruvica largest indic
model reflect moder growth competit entri
reflect limit market share gain expert call support
limit switch though remain focus new patient start
evolv calquenc well head-to-head trial data
late novemb astrazeneca calquenc approv
unlik pharma peer see china major growth initi
china top market stand-alone revenu
coupl hundr million dollar acquisit allergan
add roughli million exist revenu region bring
combin revenu exposur estim roughli million
allergan previous said view china billion dollar opportun
believ size opportun remain
combin compani even billion impli exposur
abbvi industri lead dividend yield import differenti
compani manag commit continu grow
novemb compani announc increas came follow
announc allergan acquisit send import messag
market around commit grow dividend even face larg
scale also commit reduc debt billion
billion end near-term leverag target net
debt keep credit rate better would leav enough
cash flow continu grow dividend earmark billion annual
busi develop final part compani messag
see opportun asset sale follow close allergan deal
could bolster balanc sheet
tabl content
sector perform price target portfolio manag summari
humira impact biosimilar like greater street expect
mix deal far growth still issu
still product stori key product revenu grow
concern structur margin headwind tough revers
street sentiment shift bullish consist recent stock move
valuat peer high dividend support downsid absent surpris
pipelin asset watch could drive valu
deriv cross-read els watch rel coverag
catalyst calendar limit post recent approv watch competitor data
import risk consid rel rate price target
financi model revenu build balanc sheet cash flow forecast
appendix deeper look immunolog landscap
appendix deeper look skyrizi consensu bullish
appendix deeper look rinvoq opportun across sever indic
appendix deeper look imbruvica calquenc head-to-head focu
appendix deeper look venclexta
appendix deeper look women health orilissa
appendix deeper look botox therapeut cosmet
sector perform price target portfolio manag summari
abbvi peer-best dividend yield valuat enough off-set concern
mix feel around pend allergan acquisit compani
address humira loss exclus acquir allergan continu see
growth headwind pro-forma revenu ep larg flat next
allow ampl support de-lev grow dividend enough
view drive much need valuat re-rat said see opportun
strateg move via divestitur addit deal could help reposit
compani growth anticip pressur humira biosimilar
exhibit forecast versu street modestli street stand-alone basi exclud
see greater downsid humira biosimilar risk consensu expect concern
remain focu model per share npv pro-forma
busi current equiti valu debat die
somewhat particularli addit allergan still think
swing factor specif think street underestim initi step
humira see biosimilar enter
allergan acquisit partial answer humira mix
deal deal us seem financi engin given humira cliff
strateg bolster platform think would
done face humira loss exclus loe said
like medic aesthet busi even though add much strateg
allergan busi bring much need scale footprint
account allergan revenu base women could includ ad
anoth opportun divest acquir non-cor allergan asset
effect allergan fail break busi fact
believ could opportun spin medic aesthet busi
well time ultim drive meaning return transact
ultim manag board
key product compris revenu make
grow collect compound-annual-growth-rate street skyrizi rinvoq
orilissa botox line imbruvica venclexta abbvi legaci
busi overal immunolog hematolog franchis remain backbon
compani add medic aesthet follow allergan deal
core franchis compris revenu grow
ex-humira convinc remain busi declin
per year need core potenti divestitur
could boost growth given dilut natur
think street margin high big reason
ep forecast busi seen margin move lower ad billion
synergi equat basi point margin view enough off-set
estimatesrevenu compound-annual-growth-rate compound-annual-growth-rate abbvi inc
declin side margin pressur like mount given
combin lower partnership profit grow contribut
imbruvica venclexta humira impact biosimilar also believ
like increas spend come year current
revenu pro-forma take billion plan cut allergan
side well larger biopharma peer closer
despit concern dividend yield valuat provid
support back anoth dividend increas announc novemb
yield add support level remain well ahead peer
commit grow go forward pro-forma price-to-earnings
ep near-term de-lev goal compani also lowest
valuat among peer think combin peer high dividend yield
peer-low valuat introduc decent downsid risk/reward
exhibit broken product stand-alone pro-forma basi
therapeut area revenu total revenu total us declin risk-adj crohn risk-adj ad cd uc asgi legaci fit less clear ustot continu broader cll cll aml uptak mmtotal aestheticsbotox modest growth competit indic geographi bodi system surgeri asset breast implant kybella etc total modest growth competit depress expans could growth larg viibrydtot compound-annual-growth-rate uterin fibroid risk adjustmentwomen asset lo loestrin primarilyey asset primarili restasisoth creon lupron synthroid synagi etc gi ex zenpep anti-inf etc total abbvi inc
humira impact biosimilar like greater street expect
humira compris
pro-forma
revenu declin
back
humira repres pro-forma revenu stand-alone
repres meaning swing factor valuat mani nine us humira biosimilar
could launch would without preced make competit eros
question if/when much given humira outsiz influenc
biosimilar entri unfold meaning implic stock loss exclus
loe discount clearli factor valuat still see risk skew
downsid given potenti greater expect eros anticip impact
leav effect revenu growth model without allergan
exhibit us humira revenu set fall sharpli upon entri biosimilar
intern market alreadi subject biosimilar competit million
clear biosimilar analogu humira complic forecast us
biosimilar market experienc grow pain mani earli launch perform slow
gate see exhibit averag us biosimilar penetr first year launch
measur iqvia sale data penetr month biosimilar
remicad arguabl closest comp humira perform worst year
penetr
exhibit track record us biosimilar launch mix though recent launch perform strong gate
import differ respect humira expect drive
much steeper eros curv model street first larg number
potenti biosimilar entrant one may interchang humira
would first analogu cite seen two biosimilar first
year launch wherea humira could see mani nine biosimilar enter
exhibit second given size humira evolv physician/pay attitud
expect signific focu drive biosimilar usag overal biosimilar
accept increas time humira biosimilar could face markedli differ
environ upon launch current polit climat around price
possibl see legisl chang favor biosimilar competit
final remicad success hold biosimilar due larg part rebat
strategi difficult imposs replic walk three
import trend detail final seen quick up-tak humira
biosimilar europ provid anoth imperfect analog
exhibit nine us biosimilar could launch per licens agreement
five alreadi approv
current nine
humira biosimilar
expect first
market januari
theme physician accept biosimilar physician reluct prescrib
biosimilar one major impedi greater biosimilar uptak per
proprietari survey rheumatologist dermatologist gastroenterologist
roughli overlap humira usag respond least
somewhat like switch patient biosimilar patient well
refer product percentag increas biolog treatment nave
patient expect physician accept biosimilar increas time
gener drug serv guid process gradual word physician
accept biosimilar improv still expect biggest push come
payor
exhibit poll physician respect biosimilar prescrib pattern refer appendix full survey result
respons rank scale unlik neutral like
humira biosimilarcompanyfda approvallaunch bioepi termin aug presum could like initiatetreat biosimilar biolog treatment naiv patient averag like switchtreat biosimilar patient perform well refer product averag abbvi inc
boehring ingelheim
announc pursu
approv inter-
changeabl respect
humira biosimilar
expect updat
theme eas switch interchang unlik gener drug biosimilar
must obtain separ interchang design order substitut
refer product pharmacist entail addit requir includ
data one switch studi boehring ingelheim publicli announc
initi interchang studi voltaire-x updat expect
other may follow could signific impact biosimilar uptak per
survey exhibit physician expect transit humira patient
biosimilar interchang demonstr versu
interchang demonstr account automat substitut
part assum least one interchang biosimilar
exhibit one biosimilar humira approv fda percent
patient humira would transit biosimilar
theme rebat strategi formulari dynam rebat practic employ
brand sponsor anoth reason slow biosimilar uptak per survey cost
insur two import factor influenc biosimilar
prescrib decis see appendix exampl includ exclusionari contract
product bundl discourag biosimilar use favor refer product
success strategi futur could impact polici chang and/or
outcom on-going legal challeng anti-trust lawsuit johnson
johnson remicad contract one watch
base case scenario impli per share npv humira use newco share count
approxim price target upsid downsid scenario come
per share respect repres import swing valuat
sever assumpt behind base case scenario assum biosimilar market share
increas ii assum gross-to-net impli year-
over-year net price declin price eros thereaft assum increas
rebat iii model termin growth prior model
roughli flat annual humira revenu three scenario assum modest growth
us off-set competit eros intern market rel street
consensu us humira revenu larg converg thereaft
base case npv
humira per share
compris roughli
price target
exhibit humira base case scenario yield valu per share upsid downsid valuat come
per share respect
rel modest swing humira share retent price could signific
impact valuat termin growth rate smaller impact valuat base
upsid downsid assumpt laid exhibit respect downsid
scenario easi make case realiti could wors expect given
unusu larg number potenti biosimilar entrant mani nine one
may interchang ii expect grow biosimilar accept
time
better visibl least us help set floor npv
half humira npv base case realiz prior shown exhibit
word still leav npv year greater risk swing factor
humira dcf market share net chang net price chang net price chang net price growth assum termin assum termin assum termin growth exhibit major humira free cash flow npv recogn prior biosimilar entri still leav
meaning cash flow risk
mix deal far growth still issu
see opportun
manag
strateg improv
see good less compel aspect deal view
shape manag ultim asset see opportun
signific divestitur abbvi announc acquisit allergan reaction
pend humira patent hole intent back-fil gap deal
surpris base initi neg reaction ensu recoveri
investor turnov match prefer transact us clear financi
engin think deal would pursu absenc
humira patent cliff like scale bring medic aesthet great
busi beyond struggl sever reason fulli address
growth margin headwind ii bring perceiv lower innov product mix iii
dilut faster grow immunolog hematology/oncolog franchis
hallmark still said deal potenti
view favor hindsight manag pursu strateg divestitur part
busi could improv mix pro-forma growth
deal add attract medic aesthet footprint bring scale
bolster less innov busi platform grow
compound-annual-growth-rate humira patent hole fill asid struggl
much strateg improv platform compris legaci
asset hcv women health add allergan asset includ
global ophthalmolog busi anti-infect remaind primari care asset
see exhibit said opportun allergan manag
effect break busi divest lower growth asset
improv overal mix fact see option potenti separ medic
aesthet busi time via ipo sale
exhibit abbv platform bolster medic aesthet arm scale busi also bring
notabl slower grow busi whether deem core yet determin
compani data capit market origin graphic capit market addit origin graphic
busi profromarevenu compound-annual-growth-rate add abbvi inc
pressur low
rang revenu
compound-annual-growth-rate
overal ad allergan asset come limit growth
on-going margin pressur clear exhibit caveat
remain consensu revenu margin base
seen last year allergan earn outlook disappoint
seen close downward street revis suspect would
wors entri gener restasi delay artifici hold
consensu ep next year host factor behind downward revis
rang earlier expect pipelin failur perhap notabl
exhibit remain street forecast revenu compound-annual-growth-rate on-going margin
pressur left street downward revis steadi sharp last year right
without
addit allergan slower grow revenu base dilut ex-humira
revenu compound-annual-growth-rate basi point per exhibit despit allergan modest growth ad
mix legaci product ex-humira collect ramp growth
pull overal compound-annual-growth-rate clear combin compound-annual-growth-rate
necessarili inconsist target high singl digit growth year
slower would grown without humira deal
consolid basi humira revenu compound-annual-growth-rate effect
unchang
exhibit revenu ex-humira without addit
underli ex-humira busi grow compound-annual-growth-rate without
deal materi accret stand-alone ep histor valuat
hold add support stock seen exhibit detail
pro-forma ep estim accret initi deal guidanc
peak consist outlook point indic
deal close immin spread ftc like allow
keep skyrizi see deal could possibl get done
condit close divestitur purchas price roughli billion premium
allergan prior close price time add signific new debt close
billion deal cash along million new share increas
manag near-term net leverag target
see accret
first full
year peak accret
greater
exhibit pro-forma model see ep declin peak level
see opportun divest slower grow legaci allergan asset
also potenti monet medic aesthet time effect
opportun allergan manag unlock valu split
busi per exhibit combin allergan busi
roughli revenu base collect drag overal growth
obviou asset seem fit view saleabl global eyecar
busi previous indic assess busi see
candid divestitur also see option medic aesthet busi
time think sale spin ipo busi could bring meaning
proce convinc strateg import platform
forma incom million estimate estimate estimate estimate estimate estimate commentslegaci stand-alon modellegaci stand-alon modelless net product zenpep contributiongross profit cost synergi year oper incom expens foreign exchang incom expens interest expens incom tax tax earn ep share share per rate legaci legaci net profit analysi share per exhibit break busi see similar flattish growth without although newco core
busi exclud humira grow robust compound-annual-growth-rate
total total ex cagrimmunolog legaci viberzi linzess combin vraylar botox aesthet step-up grower care set go lo loestrin key legaci legaci care anti-infect legaci sizabl primari care enter major humira revenu growth legaci revenu ex high singl digit abbvi inc
still product stori key product revenu grow
put allergan deal humira patent cliff asid remain product stori
six focu specif skyrizi rinvoq imbruvica venclexta orilissa
remain growth engin behind post allergan ad botox focu
product well given magnitud contribut grow modest
compound-annual-growth-rate model competit question linger product
like compris revenu start allergan import product
overal six product compris revenu grow
ex-humira number grow compound-annual-growth-rate
top six
product compris
increas
back
think skyrizi rinvoq deliv consensu perform
line imbruvica venclexta street orilissa botox
drill view area focu product exhibit
detail product model appendic base host
physician call survey work exhibit calcul ep impact
view product rel consensu overal larg
offset two thing note grow meaning impact
look differ mani case ii come wide vari
gross margin base varieti partnership arrang understand
import understand ultim ep impact larg line
street imbruvica product without debat given anticip head-to-head
data astrazeneca calquenc potenti competit
impact differenti shown presum ae profil
exhibit ep differenti versu street key product
note ep impact reflect variou gross margin base split uniform tax
assumpt appli
exhibit top product follow close deal
productstatusdiseasemarketcompetitiontri watchsal outlook us approv moderate-to-sever psoriasi pt elig system phototherapi eu approv psoriasispsoriasi chronic system inflammatori disea character presenc skin lesion joint involv cardiovascular diseas malign comorbiditiesskyrizi subcutan monoclon antibodi target earli launch skyrizi use failur anti-tnf/biolog inadequ respond patient popul pso pso moderate-to-severefocu target antibodi includ ilumya tremfya stelara addit data establish autoimmun disord treatment flow key includ interleukin target antibodi head-to-head studi vs and/or anti-tnf skyrizi show strong perform psoriasi versu stelara humira focu data readout piplein studi includ cd uc import piplein product monitor includ mirikizumab phase primari complet preliminari data brazikumab ibd abbvi plan divest us approv rheumatoid arthriti eu recent receiv ec approv eu market right rheumatoid arthriti rheumatoid arthriti chronic autoimmun diseas character inflamm synovium damag joint cartilag bonerinvoq oral small molecul select inhibitor us popul rheumatoid arthriti rheumatoid arthriti patient report suffer moderate-to-sever diagnosisfilgotinib select inhibitor us launch ra largest near-term threat data includ filgotiib pipelin read uc phase read jak inhibitor includ baricitinib ruxolitinib olacitinib non-select upadacitinib abrocitinib select competitor pipelin read import near-term focu filgotinib phase select data uc also import long-term safeti studi xeljanz baricitinib focus cardiovascular complic understand jak inhibitor safeti us approv mantl cell lymphoma mcl cll/sll includ del waldenstrom macroglobulinemia wm r/r margin zone lymphoma mzl chronic graft versu host diseas cgvhd eu approv r/r mcl cll wm largest indic chronic lymphocyt leukemia cll cll leukemia character increas accumul abnorm lymphocyt begin build interfer product blood cell sll consid diseas lymph node cll blood/bon marrow imbruvica oral btk inhibitor current market leader continu expans cll focu recent trial demonstr superior rang patient type help maintain growth cll indol cancer common leukemia adult leukemia biggest focu near-term calquenc acalabrutinib uptak btk inhibitor recent approv cll zanubrutinib trial cll fixed-dur regimen use venclexta could also cannib patient focu calquence/imbruvica head-to-head phase trial r/r cll elevate-rr data zanubrutinib cll sequoia trial could top-lin interim data earli venclexta combo trial focu read-through phase glow trial cll imbruvica/venclexta combo estim primari complet exhibit top product follow close agn deal continu
productstatusdiseasemarketcompetitiontri watchsal outlook us approv cll aml eu approv cll r/r largest indic also cll howev also approv acut myeloid leukemia aml common type acut leukemia adult half patient fit intens chemotherapi popul venclexta current approv venclexta oral inhibitor cll also largest indic recent label expans combin fix treatment durat sever combo trial read come year continu drive momentum similar imbruvica focu next-gen btk inhibitor howev physician becom comfort tumor lysi syndrom onboard patient onto venclexta combo trial read may share switch btk venclexta read-through btk inhibitor trial import though focu combo trial phase glow trial imbruvica/venclexta sever other includ calquenc read later year aml primari complet date phase viale-a viale-c expect multipl myeloma phase trial on-going us approv moderate-to-sever pain relat endometriosi endometriosi character presenc endometri tissu organ beyond uterine-lin caus pain symptom orilissa oral gnrh receptor antagonist estim femal us suffer endometriosi approv uterin fibroid expect femal us suffer endometrioisi symptomat orilissa hold first-to-market advantag howev focu myovant relugolix combo therapi endometriosi pain relugolix uterin fibroid obseva linzagolix endometriosi uterin fibroid myovant phase studi relugolix combin endometriosi pain spirit expect readout obseva edelweiss linzagolix phase phase studi endometrioisi import monitor orilissa pipelin focu myovant phase studi uterin fibroid liberti linzagolix phase studi primros uterin fibroid readout expect nda target us approv multipl indic broken bucket botox use cosmet therapeut hyperhidrosi smallest market eu approv use therapeut indic therapeut use indic includ movement disord migrain over-act bladder botox inject acetylcholin releas inhibitor neuromuscular block agent botox cosmet therapeut larger market botox competit dynam upcom launch temper growth botox franchis therapeut use revanc progress daxibotulinumtoxina cervic dystonia upper limb spastic plantar fasciti migrain target longer durat cosmet use botox steadili held market share player includ jeaveau posit dysport xeomin cosmet daxi bla file potenti approv therapeut use phase studi revanc daxibotulinumtoxina cervic dystonia readout expect phase studi upper limb spastic junip phase plantar fasciiti cosmet use continu focu competit dynam concern structur margin headwind tough revers
margin expans import part stori like continu
next coupl year beyond see signific margin pressur
difficult avoid specif see basi point downsid pro-forma
gross margin flow oper margin line
follow achiev peak synergi allergan deal exhibit
detail gross margin oper margin forecast reflect pressur
beyond four primari driver
neg mix shift five legaci grower imbruvica gross margin
venclexta gross margin lesser extent orilissa gross margin
gross margin low consolid newco skyrizi rinvoq
gross margin carri higher margin enough off-set first three
collect newco revenu contribut five product grow
model clearli import driver net impact
gross margin neg
humira alreadi pressur margin acceler beyond
ou gener biosimilar impact put pressur one higher margin
product outsid us us biosimilar enter begin earli
essenti expect see high margin humira revenu replac lower margin
albeit grow revenu on-going launch
allergan like add margin pressur previou concern
declin margin allergan particularli higher margin
product see gener competit restasi limit new launch growth
oper leverag expect model basi point declin oper
margin inherit
off-set cost synergi peak billon year
pro-forma revenu forecast reflect margin support basi point
larg captur clearli add import
near-term tailwind larg exhaust move first year
may pressur oper margin forecast base
abbvi need spend assum synergi come
indic would leav pro-forma spend revenu legaci
level even allergan histor spend meaning larger
biopharma peer closer expect grow focu investor
particularli intend spend billion annual pipelin type deal would
presum requir invest increas basi point would cut ep
outer year said model current reflect billion
combin spend level manag said rang
mix shift higher margin humira lower margin new launch revenu
primari driver detail bridg exhibit major swing factor
remain fast see biosimilar erod humira recent launch
perform potenti add margin pressur though would rather see
over-achiev five grower even expens margin
spend percent
revenu
whether
exhibit gross margin bridg detail impact chang mix
gross margin pressur flow oper margin off-set
synergi shown exhibit synergi captur short-term band-aid
larg spent time humira biosimilar enter
exhibit synergi provid short-term lift pro-forma oper margin
fulli realiz time humira biosimilar enter market
forecast basi point
consensu
equat roughli
ep
ad concern view street over-model oper
margin post-humira biosimilar entri exhibit illustr delta
stand-alon oper margin consensu basi point differ
driven larg oper spend street sg
street model modestli increas oper spend
assumpt humira cost save off-set
invest within busi contrast street impli absolut dollar declin
oper expens nearli million period margin differ
equat close ep
exhibit think street model stand-alon oper margin post-
street sentiment shift bullish consist recent stock move
initi neg reaction deal share ralli back aggress
sentiment around stock notabl bullish trade
announc mix best reaction continu see pressur pressur
revers perform roughli line drg last
month may inclin point comfort around deal along
sharehold turnov driver revers two factor think
seen posit earn revis follow pressur prior
year ii sell-sid rate flip equival buy versu
earlier year highest level realiti
improv sentiment like combin three longer
consensu dis-lik name
like seen meaning investor turnov base share volum trade
month lead deal averag daili volum trade million share
volum spike follow deal per exhibit month follow deal
averag daili volum million twice high least
partial back greater arb involv stock also seen stock
recov lost gain put perform last month roughli line
drg
exhibit share recov meaning follow initi neg share
reaction june acquisit announc volum also pick
share
recov earli
loss seen follow
announc agn
seen street number revis higher also like
play factor like due earli strength skyrizi rinvoq launch
deal announcedand share initi ftc holder approv dealshar back line drg perform abbvi inc
posit earli surpris manag target also move higher
exhibit detail move street revis off-set
move lower saw
exhibit seen street revis turn posit begin mid follow
steadi move like back earli skyrizi rinvoq launch upsid
current see greatest percent rate outperform last year
roughli two-third equival buy meaning earli
per exhibit indic meaning chang sell-sid
sentiment follow stock higher
exhibit broker rate time dark blue bar repres buy/overweight rate hold dark grey
underweight/sel rate light grey
ep ep revis valuat peer high dividend support downsid absent surpris
price target
base price-to-earnings
ev/ebitda driven
larg cap pharma price
price target base equal blend ev/ebitda price-to-earnings
estim ev/ebitda get us per share price-to-earnings
get us per share use expect capit structur assum
allergan acquisit close earli price target support sector perform rate
also ran discount cash flow analysi dcf get us per share larg
consist combin price target
target multipl function larg cap pharma price target framework
exhibit start histor three-year industri averag multipl adjust
company-specif factor adjust combin form discount
largest compon adjust pend us humira loss exclus
 track record reflect unsuccess billion acquisit
stemcentrx rova-t well concern around allergan deal
mix
dividend yield boast best-in-class dividend yield
appear safe even humira biosimilar enter market
growth profil difficult disentangl humira loe see
adjust captur modest revenu compound-annual-growth-rate allergan expect
declin newco margin independ humira lower spend versu peer
loe risk concentr model total humira revenu declin
billion billion absolut dollar declin billion
reflect expect entri us biosimilar well on-going ou
adjust reflect allergan integr risk includ abil
captur billion synergi well temporari boost leverag driven
deal
exhibit larg cap pharma price target framework company-specif adjust collect equat
valuat discount rel histor industri averag
note abbvi forecast pro-forma pend allergan transact
p/eev/ebitda averagem track recorddividend yieldgrowth profilelo risk p/eev/ebitdashar cap net debtenterpris valueshar estimate net leverageimpliedotherpriceimplieddebt adj target adjust price target repres addit valu relat myl/viatri contribut captur estim averageadjust factor /- forecast total abbvi inc
dcf part price target calcul yield valu per share
dcf reflect explicit forecast termin growth rate beyond
use wacc consist across large-cap pharma coverag termin
growth forecast arguabl conserv reflect key patent expir
beyond forecast period venclexta skyrizi rinvoq ii rel
low visibl earli mid-stag pipelin combin lower spend versu
exhibit dcf deriv valu per share wacc termin growth
million except per share
see much room upsid also hard justifi meaning
downsid abbvi gener dividend rel quick path de-lever
valuat collect help set floor valuat refer exhibit
expect capit alloc net leverag per model fund
combin free cash flow cash hand model share buyback
could accommod realloc resourc newco net
leverag year-end fall two year provid
flexibl accommod us humira loe
pv termin valueperpetu growthenterpris equiti valueequ valu per exhibit newco capit alloc net leverag
abbvi dividend particularli attract rel peer help support
stock see exhibit peer comparison appear capabl
gener suffici free cash flow maintain grow dividend even us
humira biosimilar enter market still reserv capit debt paydown
exhibit comparison large-cap biopharma dividend yield top list
note bar repres dividend yield base januari close price dot repres growth compound-annual-growth-rate
valuat also low end peer add downsid protect
trade consensu earn well peer averag
exhibit trade price-to-earnings well peer
base price januari base consensu estim ep
import put sector low valuat histor context
histor trade discount drg discount widen per exhibit
seen rang /- one standard deviat
current trade low end right likewis averag discount
drg also widen last year
exhibit histor valuat chart share trade roughli standard deviat discount averag
rest drug sector via drg trade discount
per exhibit drg gener within discount broader
market seen last year
exhibit histor valuat chart cont drg trade within averag discount
pipelin asset watch could drive valu
sever updat watch like pale comparison
saw skyrizi rinvoq approv within immunolog venclexta
within hematolog detail think biggest focu
also worth keep eye parkinson manag think
blockbust potenti get much focu
look progress label expans skyrizi rinvoq updat
focu skyrizi pipelin includ phase data ulcer coliti expect
phase data crohn diseas potenti psoriat arthriti expect
rinvoq pipelin updat watch includ phase data
atop dermat first half ii phase data select-psa studi
psoriat arthriti follow fda submiss mid-year iii phase
studi initi axial spondyloarthr iv potenti phase readout crohn
diseas potenti phase result ulcer coliti
oncolog readout next month focus increas imbruvica
venclexta use hematolog malign cll market get increasingli
competit gener btk inhibitor pipelin readout particularli head-to-
head data remain key focu import share data may
clarifi question around differenti think cll market import
growth anticip contribut major billion sale
sever thing watch includ phase sympatico data
investig imbruvica/venclexta combin vs imbruvica placebo r/r mcl
ii phase captiv data imbruvica/venclexta combin cll/sll iii
venclexta eu approv cll iv imbruvica shine phase data mcl
viale-a/viale-c phase data venclexta aml also await imbruvica
head-to-head studi run competitor includ phase elevate-rr/ace-
studi calquenc versu ibrutinib cll ii phase alpin
studi zanubrutinib versu ibrutinib r/r cll/sll expect complet enrol earli
lastli anticip data indic includ cgvhd fl/mzl
imbruvica posit r/r mm venclexta
orilissa approv uterin fibroid focu women health
busi orilissa approv treatment pain associ
phase elari studi orilissa uterin fibroid follow
nda submiss watch orilissa approv even
expect approv uterin fibroid billion revenu remain well
manag target billion
exhibit legaci pipelin bigger opportun label expans exist market product
diseaseasad cd uc uc imbruvicaaml prostat malignancies/solid vedotinveliparibemplicitysolid hematolog tumornsclcovarian breast lung hematolog tumorsolid hematolog tumorsolid tumorovarian breast lung depotsolid tumormyelofibrosisuterin tumoradrsv lower respiratori tumorexocrin pancreat tumorelanzanumab cord diseasescf combophas segment eyecar hematolog oncolog immunolog medic aesthet neurosci virology/hcv women abbvi inc
manag appropri given less credit allergan pipelin
program watch specif cgrp pipelin includ atogep
ubrogep could interest atogep await phase result episod
migrain clinicaltri gov primari complet date februari rel
ubrogep look color around up-tak follow announc decemb
approv product less enthusiast around allergan cvc nash opportun
expect updat well abicipar within eye care exhibit
detail current allergan program move forward though per abbvi
synergi messag close half billion save would come
expect mani review path forward
allergan assetsopt mdpfoptiv ultrapresbysolalphagan pdri eyedri ddsbimatoprost srcombiganretin pigmentosageograph ringopt fusionlumigannashglaucomamdpfglaucoma ocular htn induc edema uveitiscariprazinecenicriviroc tropifexorrelamorelinlinzessaut specturm delay releasecenicrivirocviberziadib therapeuticadmddmigrain indicationsbotoxbonteubrogepantvraylarskin qualiti glabellar linesacut migrain indicationsbotoxcariprazineviibrydmasset platysmaadjunct mddmdddeoxychol acidnivobotulinumtoxinacariprazinejowl fat reductionfaci linesbipolar cosmeticatri fibrillationindicationsjuvederm indicationscoolsculptingvis fat bulgesallodermtissu reconstructionlo loestrin fepregn preventionphas segment eyecar hematolog oncolog immunolog medic aesthet neurosci virology/hcv women abbvi inc
deriv cross-read els watch rel coverag
astrazeneca head-to-head updat calquenc next year like
import cross-read given import imbruvica sever
updat watch anticip other detail
product monitor competit updat exhibit
exhibit watch new product updat sever compani could meaning impact
revenu million
companyproductwhat watchcommentsabipicarn/an/amolecular partner collabor abipicarpdufa wet chmp opinion wet partnership molecular partner cover zoe pdufa wrinklescompetitor launch/rampcompetitor botox phase interim data cll gen coval btk inhibitor competitor ibrutinib focu compar ae profil phase head-to-head studi result vs imbruvica gen coval btk inhibitor competitor ibrutinib current data compar focu compar ae profil labsmotiva implantmotiva studi look safeti efficaci estim primari complet date march initi april support applic us approv current market ou direct competitor allergan sciencesrelugolixspirit phase data endometriosi spirit phase data endometriosi competitor orilissa endometriosi market collabor orilissaphas data result uterin fibroid estim primari complet august neurocrin collabor opportun cross-read orilissa catalyst cover brian phase uterin fibroid data competitor orilissa uterin fibroid opportun cover kennen studi atop dermat estim primari complet date juli antibodi target potenti competitor gileadfilgotinibfda approv ra eu ra approv select phase data uc select inhibitor competitor xeljanz cover brian data result prevent migrain competitor migrain market catalyst calendar limit post recent approv watch competitor data
exhibit abbvi big pharma comp catalyst calendar
datewhat phase publish result uterin fibroidsabbvful data spirit phase data endometriosi phase rosewood data abbvprimari vs secukinumab pbo phase data psoriasi vs dupix head-to-head phase readout jade compar pfehead-to-head vs dupix phase select data ucgildrinvoq competitor data pipelin fda approv uterin spirit phase data endometriosi phase shine studi mantl cell lymphoma uterin fibroid snda pdufaabbvneurocrin partner program indic primros phase data uterin phase data atop w/ gazyva cll/sll nhl supplement chmp ra supplement chmp opinionpfemodifi releas mg appov china r/r mcl r/r phase selen studi r/r phase integr studi phase data children teenag ulcer colitisllyprimari phase data ulcer coliti lucent phase data psoriasisbmyor inhibitor jak famili eu approv rheumatoid arthritisglpg/gildrinvoq phase readout ankylos phase result episod migraineabbvallergan jak/btk inhibitor combo phase data rheumatoid humira biosimilar phase voltaire-x interchang studi read-outbiswitch studi humira patient plaqu vencexta vs imbruvica monotherapi sympatico phase data r/r phase data japan approv decis rheumatoid atop dermat phase data hidraden suppurativa phase data ulcer coliti phase data phase viale-a result aml inelig induct phase viale-c result aml inelig induct w/ imbruvica sympatico phase result eu approv phase sequoia top-lin interim data cllbgnefil time unclear import risk consid rel rate price target
acquisit risk pend acquisit allergan expect close
add risk stori number way deal help fill eventu gap left
humira us loss exclus loe though introduc integr risk
brought close major complex acquisit look optim
infrastructur combin newco reduc cost deliv billion synergi year
close addit transact also introduc oper risk enter
new therapeut area ie medic aesthet though compani indic
plan leav major growth franchis untouch integr activ focu
tail valu risk humira compris revenu stand-alone compani
becom much smaller part mix newco estim compris
revenu combin compani biosimilar impact meaning swing
factor stori per analysi see exhibit laid see
bull/bear case humira loe swing factor stock well base case scenario
contribut valu per share overal price target
valuat risk valuat remain meaning discount rest group
trade consensu price-to-earnings vs comp group introduc
meaning swing factor valuat one hand bear could argu worsen
margin profil partli mix imbruvica grow also partli loss humira
integr allergan uncertainti around magnitud humira loe impact
lack strateg rational around allergan transact reason point
trough multipl group hand discount valuat add upsid
risk sector perform rate particularli manag introduc greater tail
valu via pipelin combin strong dividend yield see exhibit dividend
yield chart add downsid support furthermor allergan deal bolster cash flow
provid higher growth base point high singl digit growth revenu compound-annual-growth-rate
continu augment deal
regulatory/polit risk sever propos bill around drug price
reimburs add uncertainti potenti risk group indic
juli us sale medicar part part allergan note
mix govern payer medicar part
propos also facilit faster adopt biosimilar would also heighten
financi model revenu build balanc sheet cash flow forecast
exhibit revenu build
allergan revenu special therapeut assum gener entri alphagan-p patent loe expect aesthet separ botox modeljuvederm surgeri medicin regen contour system dermatolog almiral sep medic urolog botox model competit loe us special gross profit gross margin exhibit revenu build continu
allergan revenu gener medicinecentr nervou system bipolar depress may loe expect loe expect dec assum launch risk adjust gastrointestin gi divest deal patent protect first oral gx launch lost exclus lost exclus women loe expect loe expect loe expect diversifi us gener gross profit gross margin exhibit revenu build continu
allergan revenu ozurdex loe aesthet separ botox modeljuvederm surgeri medicin regen contour system therapeut separ botox gross profit gross margin net profit profit profit margin exhibit revenu build
 revenu us guid guid approach billionskyrizi guid million global unit compound patent apr other guid b/w skyrizi rinvoq updacitinib ra jak guid indic unit com patent approv expect earli year com immunolog unit immunolog oncologyimbruvica guid approach global unit us guid growth patent guid million global unit com patent com patent late hematolog oncolog unit hematolog oncolog hematolog mged medicaid comp cofm patent volum key ou cofm patent hcv unit split evenli btw us oustot hcv guid approach billion global exhibit revenu build continu
 revenu productscreon guid growthunit guid roughli flat y/yunit patent manuf gx hurdl like stabl guid roughli flat y/yunit enter patent sticki sharesynagi guid roughli flat guid approach millionunit gx gx other unit guid target comp matter uf pdufa comp matter product unit reflect risk adjust pipelin linetot product revenuetot net revenu unit net revenu net net revenu exhibit
 incom guid oper growthcost product profit guid guid guid salesoper incom guid salesinterest expens guid billionnet foreign exchang incom expens interest expens incom tax tax guid full year ratenet earn ep guid share share per increas announc yield price dividend yield assum annual increasesebitda guid guid guid salesoper guid salestax guid full year ratenet profit analysi guid oper share per exhibit balanc sheet
 balanc cash st receiv expens current equip asset equityshort-term portion lt debt leas payabl accru current debt leas reflect deal defer incom long-term stock held paid-in comprehens stockhold equiti liabil exhibit flow
 statement item includ net intang fair valu conting cost collabor work expens payabl flow oper busi net cash acquisit properti invest matur invest flow invest chang commerci paper chang short-term issuanc lt lt debt leas treasuri exercis stock flow financ exchang rate chang chang cash equival begin equival end appendix biosimilar/humira physician survey result
physician survey like initi new patient biosimilar rather switch exist patient
surpris said physician import decis around therapi continu view payor action bigger
drive forc around biosimilar use fact call mani open-end question exhibit notabl
appear meaning variat view across specialti
exhibit result survey physician around biosimilar use
survey questionsresponsesrheumatolog total weight total weight biosimilar approv fda like initi treatment biosimilar biolog treatment naiv patient pleas rank answer scale unlik neutral like around two-third overal respond least somewhat like start new patient biosimilar littl variat physician type could indic rel low biosimilar experi across group assum biosimilar approv fda like switch treatment biosimilar patient well refer product pleas rank answer scale unlik neutral like surprisingli physician reluct switch exist biolog patient biosimilar least somewhat like howev indic neutral idea time educ physician could move like camp littl variat physician exhibit result survey physician around biosimilar use cont
survey questionsrheumatolog one biosimilar humira adalimumab approv fda interchang demonstr patient humira would transit biosimilar physician would transit patient humira biosimilar interchang demonstr phyician would switch patient one biosimilar humira adalimumab approv fda interchang demonstr patient humira would transit biosimilar expect humira biosimilar use doubl interchang demonstr make import swing factor physician indic would switch exhibit result survey physician around biosimilar use cont
afford effect save transfer patientefficaci safeti biosimilar bioequival patient know efficaciousefficaci safeti cost/insur coverag clinic experi comfort level base journal review articl efficaci safetyefficaci specif diseaseclin trial result insur approv patient accept ultim guidelin support use interchang biosimilar efficaci reliabl product manufactur safetycopay insur coverag patient toleranceefficaci safeti side effect crossov data specif indic fda approv manufactur end pocket cost pt safetyequ efficaci interchang signific decreas cost insur mandat patient experi equal efficaci safeti biologicscoverag main determin factor effect safeti equivalencedataequival safeti efficaci brand namedata patient insur evid show efficaci safeti similar parent compound data clinic trialsfda approv evid similar effectivenesseffect formulari statu patient consentfinanci factorsefficacyformulari insur coverageefficacygood clinic data great insur coverag insur mandat use biosimilar insur hasslesefficaci like stick work mandat insur companyefficaci safetyi need data experi patient biosimilar convinc safeti efficaci differ refer productefficaci safetyi would prescrib new start would transit patient wellpleas list import factor influenc whether prescrib biosimilar exhibit result survey physician around biosimilar use cont
forc switch insur patientinterchang pt efficaci insur requir wont pay brand nameinterchang data extrapol datareliabilityindepend studieslong term safeti studi pocket cost patient cover insur robust clinic data interchang pharmaceut compani manufacturinginsur mainli insur constraintssafeti efficaci insur n/asafeti equivalenceinsur coveragenew start primari effectsinsur coverag cost patientnot comfort show mark reduc costinsur coverag drugsonli forc insurancestudi show similar efficaci indicationsinsur coverag rule overal cost healthcar thu access therapiessuffici data ensur safeti efficacyinsur coverag lack long term data interchang patient background clinic histori allergiesth patient switch renflexi wors compar remicadeinsur coverag costpati comfort level switch riski prescrib mani medicoleg factor play insur direct therapypati costtreat naiv sever diseas mandatori insur insur mandat patient costpay pressureworri qualityinsur requir priceinterchangeabilitypric efficaci safetyinterchangeabilityproven efficaci interchang proven effect compar origin product clinic studiespleas list import factor influenc whether prescrib biosimilar cont switch would depend almost entir insur mandat im requir switch patient wont sometim brand name product remain less expens patient use due co-pay coverag patient co-pay also factor drug use whether biosimilar demonstr clinic studi concern patient diseas take care basic equival origin biolog molecul abbvi inc
appendix deeper look immunolog landscap
immunolog pipelin posit captur market share autoimmun diseas
market larg shown exhibit estim market valu reach billion
us monoclon antibodi target tumor necrosi factor tnf
approv two decad saw mark uptak enbrel humira remicad
alon close billion world-wide sale despit strong use
patient either intoler inadequ respond think skyrizi rinvoq
provid meaning treatment option among jak inhibitor patient
across variou autoimmun diseas skyrizi gain momentum earli launch
set in-play psoriasi patient overal point billion market
grow remain meaning under-penetr across indic
evolv question futur around well price hold
 pressur rebat new agent introduc biosimilar becom
exhibit select immunolog treatment stratifi mechan action indic
appendix deeper look skyrizi consensu bullish
risankizumab human monoclon antibodi mab target recent
approv us april eu japan treat moderate-to-sever psoriasi
think skyrizi potenti best class mab offer conveni dose
regimen subcutan quarterli administr strong efficaci pasi pasi
clearanc increas time bring differenti rel target
therapi standard treatment anti-tnf initi forecast
meaning differ consensu skyrizi ramp billion global
risk-adjust basi billion us street drive
ep delta shown exhibit initi target back octob
skyrizi reach roughli billion earli forecast alreadi rais
exhibit us skyrizi forecast un-risk adjust
manag target introduc octob target risk adjust us
forecast compris global estim
skyrizi show impress perform earli launch anti-tnf therapi well
entrench commonli use initi biolog choic across variou autoimmun
diseas quarter launch skyrizi shown solid uptak take high share
in-play patient switch patient similar observ humira
earli launch skyrizi model exhibit reflect market share
psoriasi pso launch psoriat arthriti risk adjust
opportun crohn diseas cd ulcer coliti uc
skyrizi shown well head-to-head phase trial versu humira skyrizi produc
greater pasi spga score maintain compar ae profil strongli
support skyrizi use biolog set take market share anti-tnf
acknowledg head-to-head trial versu competitor inhibitor program would
optim order draw definit conclus across inhibitor howev clinic
trial lack regardless analyz avail clinic data report greater
magnitud primari endpoint pasi spga score compar
monoclon antibodi clinic trial think data favor support
view skyrizi potenti best-in-class inhibitor bullish launch
exhibit greater placebo-adjust pasi left spga right score compar group
wait mirikizumab phase data pso expect read
addit recent report superior pasi score taltz anti-il-
compar tremfya phase ixora-r studi although studi
demonstr greater pasi score compar tremfya greater placebo-
adjust efficaci score skyrizi versu tremfya two phase studi
skyrizi compar stelara produc greater psoriasi
area sever index pasi static physician global assess spga score
week
scoresskyrizi mg mirikizumab mg mirikizumab scoresskyrizi mg mirikizumab mg mirikizumab mg exhibit skyrizi psoriasi pso psoriat arthriti product model
risankizumab us modelest estimate estimate estimate estimate estimate estimate commentsu popul base us censu bureau datagrowth pso us pso preval psoriasi foundat patient pso moder sever preval et al sever pso patient skyrizi approv launch aprildos durat yr pasi treatment elig pt phototherapy/system treatment bodi surfac area composit put start biolog therapyskyrizi penetr pt refractory/intoler pso pt reflect failur ex-skyrizi start system receiv biologc system et al system ref/intol penetr pt pso pt pso ptsaddress pt pso market share estim address market shareskyrizi pso treat pt month pso global market expect pso revenu guidanc arthriti us pso preval psoriasi foundat patient pso pso patient psoriasi foundationpati psoriasi pt psoriat treatment refractori pt start commonli use estim overlap skyrizi treat pso pt alreadi skyriziskyrizi refractory/intoler penetr refractory/intoler pt refractory/intoler pt start biolog biolog bayaraa overlap skyrizi treat pso pso patient receiv skyriziskyrizi biolog refractory/intoler pen biolog refractory/intoler pt biolog refractory/intoler pt pt fail therapyaddress pt market share estim address market shareskyrizi treat pt month global market expect revenu revenu exhibit skyrizi crohn diseas cd ulcer coliti uc product model
risankizumab us modelest estimate estimate estimate estimate estimate estimate commentsu popul base us censu bureau datagrowth diseas cd us cd preval patient moder sever preval estimatesmoder sever cd pt biolog refractory/intoler cd pt pt fail and/or biolog therapyaddress pt cd market share estim address market shareskyrizi cd treat pt month global market exepect cd revenu data expect revenu coliti uc us uc preval patient moder sever preval estimatesmoder sever uc pt biolog refractory/intoler uc pt oral anti-tnf failur pt address pt address pt treatment eligibleskyrizi uc market share estim address market shareskyrizi uc treat pt month global market exepct revenu data expect revenu assumptionsaverag list price per price rxprice chang net net price per dose total revenu indicationdollar millionsimpli market share dollar basispsoriasi see market arthriti risk see market diseas cd risk see market coliti uc risk see market revenu immunolog market total revenuedollar millions revenu total revenueww revenu abbvi inc
appendix deeper look rinvoq opportun across sever indic
think rinvoq offer compel risk/benefit underappreci opportun
rel consensu rinvoq oral day dose select inhibitor janu kinas
approv treat rheumatoid arthriti us inadequ respond
methotrex although drug class safeti concern linger see compel risk/reward
profil rel jak inhibitor drug class similar skyrizi model near street
consensu near-term billion global risk adjust forecast
street ad ep upsid number shown exhibit
initi target back octob rinvoq reach roughli billion leav
larg delta target consensu expect
exhibit us rinvoq forecast un-risk adjust
manag target introduc octob target risk adjust us
forecast compris global estim
rheumatoid arthriti ra largest opportun target five
indic expans studi estim contribut billion risk-adjust sale
on-going studi atop dermat ad crohn diseas cd psoriat
arthriti ulcer coliti uc giant cell arthriti model risk-adjust
revenu contribut pipelin product per product model exhibit
focu long-term safeti studi understand risk/benefit profil rinvoq approv
label includ black box warn risk pulmonari embol thrombosi
note occur across jak inhibitor drug class subsequ safeti risk around
cardiovascular complic focu monitor on-going jak inhibitor safeti
studi look clear differ safeti profil across select non-select jak
inhibitor pulmonari embol thrombot
incid similar placebo
methotrex phase ra studi encourag safeti stanc ultim
watch data read long-term studi
see attract potenti market share monitor competitor progress
autoimmun disord space competit three jak inhibitor non-select
market think rinvoq demonstr clinic profil support strong uptak
base market assumpt penetr rate xeljanz ramp indic
similar patient group methotrex refractori furthermor see upsid potenti
stronger expect launch dynam recent survey rheumatologist
report expect use averag moderate-to-sever rheumatoid arthriti
patient addit galapago collabor gilead develop filgotinib
select inhibitor current phase rheumatoid arthriti ulcer coliti phase
data crohn diseas think import monitor program
clinic develop given similar mechan action howev think data
rinvoq posit captur address rheumatoid arthriti patient
rheumatoid arthriti ra chronic autoimmun diseas character inflamm
synovium damag joint cartilag bone estim affect
 popul ra patient moder sever form diseas
treatment choic driven multipl variabl includ level diseas activ
moderate-to-sever patient typic start convent synthet dmard
biolog dmard typic anti-tnf patient patient produc
inadequ respons convent synthet dmard fail achiev diseas
control anti-tnf regimen patient advanc receiv target
synthet dmard think rinvoq offer competit option patient look
initi cours treatment use oral jak inhibitor approach
exhibit rinvoq rheumatoid arthriti ra psoriat arthriti atop dermat ad product model
upadacitinib us modelest estimate estimate estimate estimate estimate estimate commentsu popul us censu bureau datagrowth arthriti ra us ra preval arthriti foundat datau patient ra sever preval ra pt moderate-to-sever diseasemoder sever ra pt refractory/intoler ra pt diseas modifi antirheumat drug start sulfasalazin hydroxychoroquin csdmard et al csdmard refractory/intoler pen csdmard refractory/intoler pt refractori ra pt blocker ebrel humira remicad etc start anti-tnf anti-tnf refractory/intoler pen estimate market biolog refractori ptstreat anti-tnf refractory/intoler pt anti-tnf refractory/intoler ra pt csdmard anti-tnf pt ra market share estim address market sharerinvoq ra treat pt month product model us ra time drug discontinu us ra revenu target ra market arthriti us psoriasi pso preval psoriasi foundat patient pso psoriasispso patient psoriasi foundationpati ra pso pt biolog refractory/intoler pt refractori nsaid csdmard anti-tnfaddress pt market share estim address market sharerinvoq treat pt month product model time drug discontinu global market expect revenu target phase data expect revenu nda submit approv dermat ad us ad preval www aafa orgu patient ad sever preval allergi foundat americamoder sever ad pt registr trialsrefractory/intoler therapi ad pt emolli phototherapi dupil address pt ad market share estim address market sharerinvoq ad treat pt month product modelsinclud time drug discontinuationsad revenu ad target global market expect revenu data read exhibit rinvoq crohn diseas cd ulcer coliti uc ankylos spondyl product model
upadacitinib us modelest estimate estimate estimate estimate estimate estimate commentsu popul us censu bureau datagrowth diseas cd us cd preval ibd caus inflamm digest tractu patient cd roch patient forecastmoder sever preval estimatesmoder sever cd pt cd pt moderate-to-sever biolog refractory/intoler cd pt fail and/or biolog therapyaddress pt cd market share estim address market sharerinvoq cd treat pt month product model cd includ time drug discontinuationsu cd revenu cd target revenu coliti uc us uc preval ibd inflamm sore larg intestineu pt uc roch preval outlookmoder sever preval estimatesmoder sever uc pt biolog refractory/intoler uc pt oral anti-tnf failur pt address pt address pt treatment eligiblerinvoq uc market share estim address market sharerinvoq uc treat pt month product model uc includ time drug discontinuationsuc revenu uc target data expect revenu spondyl us preval et al patient sever preval estim pt moder sever patient phenotypeaddress pt pt moderate-to-sever pt fail therapyrinvoq market share estim address market sharerinvoq treat pt month product model time drug discontinuationsa revenu revenu assumptionswholesal acquisit price rxprice chang net price per total revenuedollar millions revenu total revenueww revenu abbvi inc
appendix deeper look imbruvica calquenc head-to-head focu
imbruvica current approv sever indic import
chronic lymphocyt leukemia cll increas penetr continu key
driver growth venclexta also approv cll recent acut myeloid
leukemia aml key on-going trial multipl myeloma mm see compel
moat around imbruvica given meaning first-mov advantag compani
built via addit studi label expans opportun said given
potenti pressur growth momentum recent label expans astrazeneca
calquenc cll high penetr currently-tr popul question
around durabl current treatment durat estim remain line
exhibit imbruvica estim reflect continu growth though momentum slow meaning
biggest debat around competit landscap shake
introduct next-gener btk inhibitor notabl astrazeneca calquenc
acalabrutinib estim imbruvica still assum high-singl digit compound-annual-growth-rate
see exhibit assum growth rate begin moder
rel histor rate forecast declin competit entri
calquenc recent approv adult patient cll/sll us pivot
phase data ascend r/r cll elevate-tn thought higher
select calquenc higher half maxim inhibitori concentr could lead
fewer off-target effect rel ibrutinib therebi improv ae profil rel
imbruvica saw elevate-tn calquence/obinutuzumab arm saw
overal atrial fibril rate calquenc rel imbruvica
trial overal hemorrhag rate higher calquenc though
grade compar imbruvica grade exhibit full
us imbruvica ibrutinib lymphocyt leukemia cll separ build full patient segmentationtot us cll start chemo like declin timeimbruvica penetr inhibitordiscontinu rate yr followup show discontinu rate cll patient imbruvica chemo expect inc imbruvicaimbruvica monthli price per annual net price increasesgross oral cll/sll combo mono net price per month per price per year per us cll imbruvica revenu peak growth total indic us imbruvica revenu cgvhd non-cllsal growth nhl indic opptot us imbruvica revenu net revenu larg cllpaid janssen cog per filingsrev million net com patent expiri incl ped ext may point peak potenti growth us us growth y/yintern imbruvica revenu net revenuerevenu report net revenue net profit split growth year-over-year sale report global revenu billionsal growth billion incl part intenational sale abbvi inc
comparison though note trial directli compar also saw
increment improv efficaci calquenc hazard ratio vs imbruvica
estim month vs imbruvica though believ
improv ae profil greater driver uptak overal physician outreach
show unlik wholesal switch calquenc particularli exist
patient well-control expect physician start put
new start onto calquenc imbruvica vast major plan continu
primarili use imbruvica ibrutinib intoler patient popul estim
cll obviou initi target group calquenc howev improv safeti data seen
thu far similar efficaci offer compel altern
key upcom data set calquenc elevate-rr trial true head-to-head
ibrutinib r/r cll data expect first-mov
advantag allow build larg bodi data around imbruvica within specif
patient group ecog studi young/fit etc help maintain momentum
physician spoke note past imbruvica data patient popul still
gave comfort calquenc would likewis similarli efficaci group
without need separ trial though view share rais
concern us around strength moat longer term expect commun
oncologist treat major cll patient slower switch remain
furthermor behind beigen zanubrutinib anoth second gener btk
inhibitor watch phase cll trial on-going see exhibit catalyst calendar
sequoia interim read expect earli alpin trial r/r cll/sll
head-to-head ibrutinib enrol expect complet earli
exhibit comparison cll note trial apples-to-appl upcom elevate-rr studi
compar calquenc imbruvica r/r cll
longer term focus potenti shift treatment paradigm physician
becom comfort venclexta cll move patient toward fixed-dur
regimen ramp-up phase intens physician may hurdl
prescrib commun oncologist fix durat improv ae profil may take
share imbruvica long-term venclexta approv r/r cll
physician channel check call tumor lysi syndrom key concern
requir monitor ramp period also clear interest potenti
fix durat regimen would allow drug holiday particularli younger/fit
patient commun oncologist may reluct start patient
venclexta despit fix durat treatment month month
familiar abund data imbruvica btk inhibitor gener offer
compel moat physician check come back strong enthusiasm around
venclexta expect imbruvica remain gold standard cll expect
see gradual shift particularli long-term venclexta combo studi read see
exhibit potenti cannib imbruvica venclexta concern
nearli continu durat treatment imbruvica could becom less favor
option particularli younger patient imbruvica follow-up analysi saw
median durat respons reach month r/r
patient see risk fix durat combo begin gain favor
calquenc acalabrutinib imbruvica cll/sllpresent lancet armschlorambucil obinutuzumabcalqu obinutuzumab chang vs comparatortreat armschlorambucil obinutuzumabimbruvica obinutuzumab chang vs comparatorprimaryprimari median f/u median f/u high-risk orr high-risk cr os os monthso median f/u mth endpointsoth endpointsundetect mrd overal undetect mrd mrd bone marrow undetect mrd bone mrd peripher blood undetect mrd peripher ratiohazard ratioadvers eventsadvers eventsteaeoveral grade grade grade grade lead lead exhibit data catalyst read-through imbruvica venclexta star rang impact
said imbruvica highli penetr cll clearli still runway
growth popul tradit treat chemo sever recent
studi support increas use imbruvica particularli popul tradit
treat chemotherapi regimen physician check continu point allianc
particularli impact practic chang studi allianc studi
elderli fit popul one physician check note clinic
upward patient would fit categori said popul
typic treat bendamustine/rituximab declin usag though still
popular amongst commun oncologist studi young/fit popul
typic given aggress chemo fcr debat around studi
design rituximab combo without ibrutinib monotherapi arm power ighv
statu safeti seen patient note strike believ increas
uptak under-penetrated patient group add runway continu growth
productindicationeventtimingpotenti cllphase sequoia interim top-lin earli benda/rituximab primari complet oct file time unclearr/r flpivot ph rosewood readprimari complet jan obinutuzumabr/r cll/sllphase alpin primari completionprimari complet feb ibrutinib expect complet enrol earli file time mclenrol phase trial primari complet juli zanubrutinib vs rituximab chemocalquencecllapprovalapprov late design mono elevate-tn ascendcalqu vs cllphase dataprimari complet march expect first true head head trial read-out cllcalquenc cll w/o dataprimari complet aug expect venclextar/r mclphase sympatico dataread-out expect cll/sllphase captiv dataprimari complet dec durat combo remain focu cll phase complet feb durat combo remain focu cll w/o mutationphas dataprimari complet jan expect cll young/fitsnda approvalsubmit data mclphase shineprimari complet may expect fl/mzlphase seleneprimari complet juli expect cgvhdphase integrateprimari complet juli manag could million peak fl phase perspectiveprimari complet jan aml inelig induct therapyphas viale-aprimari complet feb billion peak opportun data confirmatori aml inelig induct therapyphas viale-cprimari complet jul billion peak opportun data confirmatori posit r/r mmphase canovaprimari complet jan hold lift data piv trial begin cll phase combo gazyvaprimari complet apr durat combo could allow drug holiday cll phase combo imbruvica gazyvaprimari complet oct durat combo could allow drug holiday cll phase combo imbruvica gazyvaprimari complet june durat combo could allow drug holiday ibrutinibbeigeneastrazenecaabbvi abbvi inc
appendix deeper look venclexta
see potenti upsid given fix durat treatment cll increas bodi
combo data label expans start acceler penetr physician
consult point tumor lysi syndrom tl subsequ need close
monitor logist challeng main drawback believ continu data
gener cll part fixed-dos combin regimen help drive greater uptak
outer year said includ multipl myeloma mm estim
drive lower number rel consensu outer year note abbvi
venclexta estim assum success mm biomark defin patient
popul mm
exhibit venclexta product model exclud mm label expans opportun
us venclexta lymphocyt leukemia cll separ build full patient segmentationtot us cll global hematolog malign market incid rate new treatment per roch outlook see cll/aml patient model del untreat cll r/r relapsed/refractori del untreat cll cll million market penetr start chemo penetr penetr excl penetr penetr totaldiscontinu rate murano cll patient venclexta cll patient venclexta appr cll del w/o del cll patient venclexta venclexta monthli price per annual price increasesgross wk ramp-upnet price per month per patient month mo treat orr label dor moavg patient month mo treat orr label dor mou cll venclexta revenu growth myeloid leukemiaian age late survivalincid rate new aml discontinu rang elig intens chemo per seer aml year year inelig intens chemo appr newli diagnos aml chemo-inelig penetr market half address herediscontinu rate chemo-inelig aml pt monthli price per dose combo azacitidine/decitabin gross price per month per patient month us aml venclexta revenu growth venclexta revenu split ussal growth com patent exp venclexta revenu com expir may growth y/i report guid millionsal growth nomin sale potenti abbvi inc
fix durat treatment potenti shift cll paradigm though expect
penetr gain momentum commun oncologist becom comfort
tl support data gener current gold standard remain imbruvica
indefinit durat therapi follow-up analysi median durat
respons reach month r/r patient contrast
venclexta label indic month treatment median dor month
month r/r median dor month respect furthermor number
combo studi underway studi imbruvica/venclexta combo
studi calquence/venclexta combo other would allow drug
holiday potenti manag tl
aml approv add foothold potenti billion market opportun abbvi
estim aml market billion us half inelig intens
chemotherapi beyond aml also pursu indic multipl myeloma mm
canova trial look posit r/r mm mm label expans
opportun reflect estim canova restart follow clinic hold
annual incid us posit r/r mm estim
overal popul see potenti upsid estim drive outer-year delta
rel consensu estim
appendix deeper look women health orilissa
expect primari growth driver abbvi women health busi
orilissa current approv market us endometriosi
approv uterin fibroid expect mid acquisit allergan add
million portfolio product led oral contracept lo loestrin run-rat
close million per year still grow mid-teen follow sever year
market patent protect februari base appel confirm
patent expect women health platform deliv solid growth
well manag target orilissa base result
cautiou physician dialogu survey well competit concern next two
mechan action well understood orilissa oral administ small
molecul gonadotropin-releas hormon gnrh receptor antagonist gnrh serv
releas hormon hypothalamu pituitari caus product two
hormon lutein hormon follicl stimul hormon women
hormon caus ovari produc estrogen progesteron lead
uterin fibroid endometriosi orilissa serv shut gnrh hormon
axi lessen pain endometriosi fibroid size
orilissa elagolix current approv endometriosi endometriosi occur
tissu uterin line present organ usual lower abdomen pelvi
lesion outsid uteru develop hormon like estrogen make grow
creat pain cramp could creat issu get pregnant perhap much
women condit standard care hormon contracept control
hormon build nsaid control pain follow potenti surgeri believ
approxim women childbear age endometriosi
use patient model exhibit orilissa approv juli first
fda-approv treatment manag moder sever pain associ
endometriosi decad model peak penetr overal
patient treat endometriosi drive forecast million
approv uterin fibroid expect next year file snda last august
approv uterin fibroid pdufa like time-frame similar
size patient market given preval uterin fibroid could quicker ramp
therapi target treatment menstrual bleed phase studi primari
endpoint defin percentag women menstrual blood loss volum
less ml final month therapi reduct menstrual blood
loss volum baselin final month orilissa deliv placebo adjust respond
rate offer promis said given limit durat use hurdl
regard bone miner densiti bmd concern mention reimburs hurdl via
prior author taken cautiou approach model revenu
risk adjust million
exhibit orilissa market model consensu abbv target
import competit consider three gnrh competitor
expect make market uterin fibroid endometriosi orilissa
approv first latter myovant obseva far behind slightli
differ approach detail exhibit ultim expect serv
modelactualest estimate estimate estimate estimate estimate estimate commentsu femal popul us censu bureau datagrowth preval epidemiolog datapati endometriosi myov datadiagnos symptomat epidemiolog dataorilissa target popul indic diagnos per yearmyov see symptomat w/o relieftreat rate see diagnos treatedtot patient treat fail controlledorilissa penetr rate treatment prior author requiredtot endometriosi patient month revenu aug fibroidsuterin fibroid preval epidemiolog data ncbi patient uterin fibroid see preval broad rangesymptomat epidemiolog dataorilissa target popul satisfi oc s/pain medsmyov see symptomat therapytreat rate see diagnos treatedtot patient treat penetr rate myov nda expect uterin fibroid patient obsv phase nda file month use far clearuterin fibroid fibroid revenu model bigger opportun uterin fibroid pdufa revenu launchpric assumptionslist price per price rxprice chang net price per month treatmentendometriosi fibroid orilissa fibroid risk-adjust us revenu guid billion orilissau risk adjust portion market see clear winner point base upon avail
exhibit orilissa competit landscap obsv myov progress gnrh antagonist far behind
partnership econom neurocrin bring lower gross margin june
abbott separ neurocrin announc global agreement
develop commerci elagolix time product recent complet
phase studi endometriosi intent pursu uterin fibroid abbott receiv
world-wide right next-gener gnrh antagonist women men
return abbott made up-front payment million fund cost mileston
million royalti believ rang royalti agreement
effect lower product gross margin believ rang
elagolix orilissalinzagolix obsv relugolix myov develop stage endometriosi em snda submit aug expect pdufa edelweiss us us eu initi spirit phase studi expect estim launch data takeawaysplacebo adjust respond pelvic paintbdtbd co-primari endpoint dymenorrhea pelvic paindevelop stage uterin fibroid uf snda submit aug expect pdufa primros phase data expect nda/eu file expect late phase report nda file expect file expect data takeawaysplacebo adjust respond rate adjust respond rate use qd use bid without food qd low high dose qdadd-backmonotherapyno low dose abil titrat higher dose add-backy combin relugolix estradiaol progestina considerationshot flush versu placebobmd versu placebo densiti hot flash compar placebooth considerationsfirst market endometriosi like uterin fibroid welldifferenti via abil start lower dose add-back titrat higher add-back target studi potenti ethnic varianc result placebo differ versu othersbackground compoundlicens world-wide right milestones/fund royalti go forward exclus world-wide right ex-asiain-licens takeda hold right us eu takeda approv japan uf proport women ml menstrual blood loss per cycl reduct menstrual blood loss alkalin hematin method appendix deeper look botox therapeut cosmet
botox would provid larg global product split therapeut
cosmet use approv expect botox compris combin
allergan revenu product major driver histor allergan
grow mid-teen half contribut come therapeut
indic build ad product high barrier revenu
base remaind revenu sourc cosmet use seen steadi
market growth posit demograph trend overal roughli botox
revenu come us gross margin believ favor
tax statu given irish-bas intellectu properti howev competit dynam
shift temper botox growth model sale compound-annual-growth-rate
still grow
botox therapeut two factor play first entri cgrp
compet botox migrain us botox margin revenu close
million third global therapeut revenu see stabl use
botox migrain believ growth deceler close
flattish outlook bring overal growth two factor
contribut first believ import indic within therapeut
approv movement disord migrain over-act bladder etc
depress possess meaning upsid option also challeng clinic
hurdl view second expect competit road revanc
progress daxibotulinumtoxina daxi cervic dystonia phase upper limb
spastic phase plantar fasciiti phase migrain preclin compani
look make durat claim longer botox success could repres
competit risk off-label detail revanc clinic time see note
post meet compani link
botox cosmet signific debat around allergan abil hold
price net discount promot share follow entri evolu
jeaveau spring year jeaveau fourth toxin us market
physician offic stock
understand investor trepid around price pressur market share fall-
jeuveau target number posit behind botox ahead dysport
xeomin botox held steadi market share three player market
launch year revanc expect launch cosmet daxi
quickli turn five player market continu believ botox
name keep leadership posit along steadi market growth facial
exhibit model slow botox growth back new competit therapeut cosmet
 botox million actualest estimate estimate estimate estimate estimate estimate botox compound-annual-growth-rate reflect slowdown sale growth botox botox hyperhidrosi botox therapeut botox cosmet treat glabellar line botox botox hyperhidrosi botox us botox ou botox therapeut botox therapeut total botox therapeut major indic depress sale growth enter market assum growth slowdown cgrp entrysal growth us therapeut sale growth oab oab total sale growth botox includ botox therapeut sale movement sale growth therapeut growth cosmet botox cosmet aesthet segmentssal possibl price pressur pick total botox cosmet approv four toxin nowsal growth expect jeauveau becom dysport cosmet growth competit eros time abbvi inc
